Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

DISEASE CHARACTERISTICS: * Diagnosis of neuroblastoma by 1 of the following methods: * Histopathology * Bone marrow involvement AND elevated urinary catecholamines * High-risk disease, defined by 1 of the following: * Stage 4 disease with MYCN amplification (any age) or without MYCN amplification (\> 18 months of age) * MYCN-amplified stage 3 disease (unresectable and any age) * MYCN-amplified stage 4S disease * Metastatic disease * Tumor progression or persistent disease (at metastatic or primary site) after intensive conventional chemotherapy * Must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive MIBG or PET scans) or measurable (CT scan or MRI) disease documented after completion of prior systemic therapy PATIENT CHARACTERISTICS: * Platelet count \> 25,000/mm\^3 * ANC \> 500/mm\^3 * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history of allergy to mouse proteins, beta-glucan, mushrooms, or yeast * No active life-threatening infections * No severe major organ toxicity * Concurrent toxicity must be ≤ grade 2 except for the following, which may be grade 3: * Myelosuppression * Hearing loss * Alopecia * Anorexia * Nausea * Hyperbilirubinemia from TPN * Anxiety * Hypomagnesemia * No prior HAMA titer \> 1,000 U/mL by ELISA PRIOR CONCURRENT THERAPY: * No concurrent supplemental beta-glucan in food (e.g., bran cereals or mushrooms) or as complementary medicine * No other concurrent systemic anticancer medications (e.g., hormonal agents, chemotherapy, investigational agents, or immunotherapy) * Concurrent isotretinoin allowed after the second course of study treatment is completed or if the patient develops human antimouse antibody (HAMA)